Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06364774 · ClinicalTrials.gov registry record · Phase 1
ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
A Phase 1 study of Beta-Thalassemia, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06364774 is a Phase 1 study of Beta-Thalassemia that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 12 participants, below the 180-participant average among 14 other Beta-Thalassemia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06364774, a Phase 1 study of Beta-Thalassemia, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The main goal of this study is to find out if the blood disorder called transfusion-dependent beta thalassemia can be safely treated by modifying blood stem cells. This is done by collecting blood stem cells from the subject, modifying those cells, adding a healthy beta globin gene, and then giving them back to the subject. It is hoped that these modified cells will decrease the need for blood transfusions. The gene modified blood stem cells are called CHOP-ALS20 ("study drug"). This experimental gene therapy has not been tried on human beings before and is not FDA approved.
Conditions Studied
Interventions
- BIOLOGICAL ALS20
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-04-14 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06364774
The ClinicalTrials.gov registry entry for NCT06364774 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 14 other Beta-Thalassemia trials with a reported enrollment target (93% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Beta-Thalassemia appearing as the primary indexed condition, and to 1 intervention - of which ALS20 is the first listed.
NCT06364774 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06364774 about?
NCT06364774 is a clinical study titled "ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia". The main goal of this study is to find out if the blood disorder called transfusion-dependent beta thalassemia can be safely treated by modifying blood stem cells. This is done by collecting blood stem cells from the subject, modifying those cells, adding a healthy beta globin gene, and then giving ...
What is the current status of trial NCT06364774?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-04-14. Estimated completion is 2027-12-31.
What conditions does trial NCT06364774 study?
This clinical trial studies the following conditions: Beta-Thalassemia.
What interventions are being tested in trial NCT06364774?
The interventions under investigation include: ALS20 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06364774?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06364774 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Beta-Thalassemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
-
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
RECRUITING
-
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
RECRUITING
-
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
RECRUITING · Phase 2
-
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.